The Next Patient — the week in health care AI, compressed so you can read it once and know what changed. Underlined source phrases open the underlying record.

Anthropic and HHMI's Janelia Research Campus opened a research preview of the Model Hardware Standard — one shared interface that lets an AI agent discover, run, and script programmable lab equipment. Genentech, Carnegie Mellon, and QuEra ran it early; an agent-written script at QuEra recovered a laser lock in 695 of 700 trials.

Discovery is the pipeline every new treatment, test, and peptide comes out of. Equipment integrations that took weeks fall to hours, and experiments can run around the clock — which moves the date when the next thing arrives in front of patients. It is a research preview, and the record says plainly that expert oversight is still required.

One call, flagged as ours: hardware standards win on adoption, not on demos. If more instrument makers ship drivers for it by year end, this becomes the layer AI-run labs standardize on; if none do, it stays a well-funded pilot. The public partner list is what would change our mind, either way.

FDA authorized Abbott's Libre Duo 10 Day system (Aug 25) for people 2 and older living with diabetes — the first device to track both markers continuously. Metabolic readings that used to mean a lab draw and a schedule now stream from a sensor on the arm, and care built outside hospital walls is exactly where that data lands.

Lilly registered a trial of orforglipron — a daily pill — in people who are overweight but not yet obese (Aug 31), and a second sponsor registered a once-monthly obesity injection the same day. Weight-loss care built around weekly injections gets rewritten twice: first no needle, then no monthly visit. Markets are moving.

FDA approved Mimrylo (rusfertide) for polycythemia vera (Aug 28) — a first-in-class peptide therapeutic. That puts regulatory footing under a category that has mostly lived outside it.

05 — Google's Co-Scientist moved into working labs — materials, biology, and medical reasoning — including a technique that beat six frontier models in blinded physician review (Aug 28). Two hands-in-the-lab stories in one week is a direction, not a coincidence.

06 — An agentic AI classified breast-ultrasound malignancy with no fine-tuning in npj Digital Medicine (Aug 29). Ultrasound is the cheap, portable modality — the one that moves screening out of the radiology suite.

07 — A three-minute lesson on the false-positive paradox measurably recalibrated clinicians' trust in AI aneurysm detection, in a multinational randomized study (Aug 28). Adopting AI screening may be a training problem before it is a technology problem.

08 — "The beginning of the end for manual chart review": LLM-built clinical databases (npj Digital Medicine, Aug 27). The documentation layer every care operation pays for is becoming a model call.

09 — HHS extended the comment period on scheduling 7-hydroxymitragynine — a kratom-derived ingredient sold on supplement shelves — toward Schedule I (Aug 26). Where supplements are on the menu, this docket redraws part of it.

10 — FDA extended the effective date on its estrogen-androgen fixed-combination ruling (Aug 27) — products in that hormone-therapy class stay marketable while the docket runs.

11 — Opalescence launched prefilled whitening trays (Aug 31) — an over-the-counter product stepping toward chairside aesthetics. Markets are moving in both directions.

12 — A new dermal filler entered a head-to-head trial against Juvéderm Volift for nasolabial folds (Aug 31) — direct competition arriving in a category that has had little of it.

13 — FDA approved Rasonque (daraxonrasib), a first-in-class RAS inhibitor for pancreatic cancer (Aug 26). It crossed into mainstream weekend coverage — which is when patients start asking.

14 — NIH opened a public hearing on reorganizing NIAID (Aug 31) — the system changing itself, on the record.

15 — npj Digital Medicine framed "social analgesia" — AI empathic interaction as a chronic-pain care concept (Aug 26).

16 — Funding: EIT Pharma closed an oversubscribed $35M Series A for late-stage infectious disease, and Convergen raised $15M for protein-aggregation therapeutics (both Aug 31).

17 — Reported and press-only, carried as flagged until a primary record exists: cyborg cockroaches as micro-paramedics.

One issue a week, 52 a year, sources attached.